Steve Strazza brings a unique perspective to the world of Technical Analysis due to his diverse background. Steve found an affinity for financial markets during his first job out of college as a big-4 CPA auditing some of Wall Street’s largest broker-dealers, such as Interactive Brokers and Morgan Stanley. Steve then worked in the Asset Management industry in a variety of roles including Controller for a private equity start-up, Fund Accountant at two large hedge funds, and most notably as a personal Accountant for Steve Cohen at SAC Capital and Point72. Steve has spent recent years writing as an Independent Research Analyst while working on a variety of Fintech projects for companies such as the TradeXchange and Deloitte & Touche. He also continues to practice part-time at his father’s CPA firm. Naturally, Steve began his research career using the financial statement analysis skills he gained as an accountant. After learning the flaws of fundamental analysis first-hand through his research career as well as his experience auditing public companies, he transitioned his investing style to focus primarily on price action. Steve holds an MBA from Fairfield University.
We've had some great trades come out of this small-cap-focused column since we launched it back in 2020 and started rotating it with our flagship bottom-up scan, Under the Hood.
For the first year or so, we focused only on Russell 2000 stocks with a market cap between $1 and $2B.
That was fun, but we wanted to branch out a bit and allow some new stocks to find their way onto our list.
We expanded our universe to include some mid-caps.
Nowadays, to make the cut for our Minor Leaguers list, a company must have a market cap between $1 and $4B.
And it doesn't have to be a Russell component — it can be any US-listed equity. With participation expanding around the globe, we want all those ADRs in our universe.
The same price and liquidity filters are applied. Then, as always, we sort by proximity to new...
Every weekend, I dive into our insider activity tracker looking for the most interesting and bullish buys — and this week, we had a handful of Wall Street titans hit our list… as well as more activity in biotech.
Here’s the most notable activity:
Point72 Asset Management, led by Steve Cohen, increased their stake in Celldex Therapeutics $CLDX from 3.95% to 6.70%.
That’s a major step up — and it comes after a string of bullish biotech activity in recent weeks.
Carl Icahn boosted his position in Centuri Holdings $CTRI, going from 6.02% to 7.22%.
He’s already a known activist — and when he adds to a position, it’s rarely passive.
Over in entertainment, Discovery Capital Management just re-established a 6.80% stake in AMC $AMC.
Technically not an original filing — but they dumped this name at year-end 2024 and now they’...
I loaded up on the $BIDU 9/19 $100 calls and added exposure through the $KC 8/15 $15 calls.
These setups look powerful, and if we see a bid in Chinese stocks, I want to be in front of it.
They moved against us as soon as we got in. That hurts in the case of KC but doesn’t affect the BIDU position much. We went further out than usual and higher delta on BIDU. All that really means in my mind is a lower risk/reward… or a more conservative trade.
At the same time, I went back to the well on $SMCI.
